Cory Jubinville, PhD, an analyst from LifeSci Capital, maintained the Buy rating on Verve Therapeutics (VERV – Research Report). The associated price target is $55.00.
Cory Jubinville, PhD, has given his Buy rating to Verve Therapeutics due to a combination of factors that strongly support the promising future of the company. The FDA’s clearance of its Investigational New Drug (IND) application for VERVE-101, a therapy for heterozygous familial hypercholesterolemia (HeFH), is one of the key factors driving the positive outlook. This approval is a testament to the FDA’s increasing acceptance of in vivo gene/base editing therapies. Additionally, Verve is expanding its US operations allowing more patients to participate in their clinical trials, which further strengthens the position of the company.
Further bolstering Jubinville’s Buy rating is the fact that Verve has established a clear framework for IND clearance, which minimizes risks for other key base-editing programs in the pipeline. The IND clearance also validates the overall data to be presented at the American Heart Association (AHA) meeting, which is expected to be largely positive. The company’s robust preclinical-to-clinical translation of VERVE-101, combined with the FDA’s initial safety affirmation, are other important factors contributing to the Buy rating. Jubinville also noted that potential short-term clinical safety signals that might arise are likely to be associated with manageable transaminase elevations, with which the FDA appears to be comfortable. This highlights VERVE-101’s potential as a single-course treatment for HeFH, further strengthening the company’s prospects.
See today’s best-performing stocks on TipRanks >>
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Verve Therapeutics (VERV) Company Description:
Verve Therapeutics Inc is a genetic medicines company pioneering the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. Its initial programs focus on PCSK9 and ANGPTL3, two genes that regulate levels of blood lipids. The company is developing these gene-editing treatments for patients with familial hypercholesterolemia, a genetic disease that causes life-long severely elevated blood cholesterol.
Read More on VERV:
- Verve Therapeutics Announces Clearance of Investigational New Drug Application by the U.S. FDA for VERVE-101 in Patients with Heterozygous Familial Hypercholesterolemia
- William Blair biotech analyst to hold an analyst/industry conference call
- Verve Therapeutics to present Phase 1b data on HeFH candidate
- Verve to Present Interim Data from the heart-1 Phase 1b Clinical Trial of VERVE-101 in HeFH Patients at the American Heart Association’s Scientific Sessions 2023
- Verve Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference
